- The Daily Innovation Newsletter
- Posts
- June 2nd 2025
June 2nd 2025
Max Gray
June 02, 2025
The Daily Innovation Newsletter
Enjoying this newsletter? Know someone who would too? Forward this email to them!
June 2nd 2025
💻 Technology
Japanese scientists have set a new world record by transmitting data at 1.02 petabits per second across 1,808 km using a 19-core optical fiber the same size as current infrastructure. The team, presenting their findings at OFC 2025, solved key challenges in long-distance amplification and signal interference, enabling ultra-fast, high-capacity communication over existing-sized fibers. Developed by Japan’s National Institute of Information and Communications Technology (NICT), this innovation paves the way for future data-heavy applications like 6G, AI, and the Internet of Things.
🚘 Transport
Germany’s Rheinmetall has completed a successful year-long pilot of its discreet curbside EV charging module, designed to replace traditional curbstones and deliver up to 22 kW of power without obstructing pedestrian areas. The IP68-protected system integrates into city infrastructure, supports app-based activation, and proved over 99% reliable in real-world conditions. Following strong user feedback and over 2,800 test charges, the charger is now ready for wider rollout in dense urban environments.
🚀 Space
Chinese aerospace firm Space Epoch has successfully performed a vertical sea recovery of its Yanxingzhe-1 rocket, demonstrating reusable launch capability similar to SpaceX’s. The 26.8-meter rocket reignited its engine mid-descent and executed a controlled splashdown off Shandong’s coast, marking a breakthrough for China’s private space sector. This achievement positions Space Epoch among several Chinese firms rapidly advancing reusable launch systems.
💊 Healthcare
🇮🇹 Italian scientists develop newborn gene therapy that reverses blood diseases with single injection
Researchers at Italy’s IRCCS San Raffaele Scientific Institute have created a gene therapy that edits blood stem cells directly in newborns’ bloodstreams, reversing three severe genetic diseases with a single injection. Targeting a brief window after birth when stem cells circulate freely, the therapy corrected conditions like Fanconi anemia, immune disorders, and brittle bone disease in mice. Published in Cell, the approach offers a less invasive and potentially more accessible alternative to traditional ex vivo gene editing.
Researchers in Japan are set to launch human trials in 2025 for artificial blood made from processed hemoglobin that works across all blood types. Developed by teams at Nara Medical University and Chuo University, the purple-tinted fluid can be stored at room temperature for up to two years, making it ideal for disaster zones and remote care. If successful, this could become the world’s first widely deployable artificial blood, addressing donor shortages and compatibility challenges.
🇬🇧 UK researchers develop twice-yearly injection to lower blood pressure and cut cardiovascular risk
A UK-led clinical trial has shown that a single injection of zilebesiran every six months significantly reduces blood pressure when added to standard treatment. Developed using RNA interference, the drug targets a liver protein to relax blood vessels and improve blood pressure control. The findings, published in JAMA by researchers at Queen Mary University of London, suggest a major advance in managing hypertension, a key risk factor for heart attack and stroke.
P.S.
This Wednesday, I’m launching something new. If this newsletter keeps you informed, what’s coming next is built to give you an edge, with deeper signals and actionable takeaways to help you grow, both personally and professionally.
That’s all for today, please reply to this email if you have any comments or feedback, we’d love to hear from you about what we can do better!
Have you enjoyed this email? Make sure to share it with your friends and colleagues.
See you soon,
Max
Reply